

Bhagirathbhai R Dholaria

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8316317/publications.pdf>

Version: 2024-02-01

87
papers

2,302
citations

304743

22
h-index

243625

44
g-index

88
all docs

88
docs citations

88
times ranked

3837
citing authors

#	ARTICLE	IF	CITATIONS
1	Next generation of immune checkpoint therapy in cancer: new developments and challenges. <i>Journal of Hematology and Oncology</i> , 2018, 11, 39.	17.0	597
2	Cancer immunotherapy beyond immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 8.	17.0	174
3	Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 978-986.	3.5	141
4	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2901-2912.	1.6	124
5	Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. , 2018, 6, 129.		95
6	Emerging therapeutic agents for lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 138.	17.0	77
7	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	1.2	65
8	Overview of approved CAR ^T therapies, ongoing clinical trials, and its impact on clinical practice. <i>EJHaem</i> , 2022, 3, 6-10.	1.0	63
9	Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. <i>BioDrugs</i> , 2019, 33, 45-60.	4.6	61
10	CAR T cell therapy in solid tumors: A review of current clinical trials. <i>EJHaem</i> , 2022, 3, 24-31.	1.0	57
11	Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1239-1246.	2.0	56
12	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	3.5	51
13	The use of venetoclax [®] -based salvage therapy for post [®] hematopoietic cell transplantation relapse of acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1006-1014.	4.1	45
14	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20.	1.2	45
15	Spicy Seizure. <i>American Journal of the Medical Sciences</i> , 2012, 344, 67-68.	1.1	44
16	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	7.1	44
17	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 186, 767-776.	2.5	31
18	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2766-2775.	7.2	30

#	ARTICLE	IF	CITATIONS
19	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	7.2	28
20	How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID-19 threat?. <i>British Journal of Haematology</i> , 2020, 189, 239-240.	2.5	27
21	Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. <i>Leukemia</i> , 2022, 36, 856-864.	7.2	26
22	Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. <i>Cancer Medicine</i> , 2018, 7, 4932-4942.	2.8	25
23	Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 843-851.	7.0	25
24	Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 345-356.	2.3	21
25	Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. <i>Immunotherapy</i> , 2019, 11, 577-584.	2.0	18
26	Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 497.	3.7	17
27	Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. <i>Leukemia Research</i> , 2018, 67, 1-5.	0.8	14
28	Impact of total body irradiation vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1200-1208.	4.1	14
29	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14
30	Securing the graft during pandemic: are we ready for cryopreservation for all?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e145-e146.	2.0	14
31	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy. <i>British Journal of Haematology</i> , 2021, 193, 1060-1075.	2.5	13
32	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 86.e1-86.e8.	1.2	13
33	Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study. <i>Blood</i> , 2021, 138, 1647-1647.	1.4	13
34	A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3) Tj ETQq0 0 0gBT /Overlock 10 T		
35	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2020, 34, 1144-1153.	7.2	12
36	Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 76.	17.0	12

#	ARTICLE	IF	CITATIONS
37	Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI. <i>Blood Advances</i> , 2019, 3, 1950-1960.	5.2	9
38	Sequence of Splenectomy and Rituximab for the Treatment of Steroid-Refractory Immune Thrombocytopenia: Does It Matter?. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2199-2208.	3.0	9
39	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 171.e1-171.e8.	1.2	9
40	New targets for CAR T therapy in hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101277.	1.7	9
41	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 83.e1-83.e9.	1.2	9
42	Role of bridging therapy during chimeric antigen receptor T cell therapy. <i>EJHaem</i> , 2022, 3, 39-45.	1.0	9
43	Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience. <i>British Journal of Haematology</i> , 2022, 198, 1073-1075.	2.5	9
44	Necrobiotic xanthogranuloma associated with monoclonal gammopathy: successful treatment with lenalidomide and dexamethasone. <i>Annals of Hematology</i> , 2016, 95, 671-672.	1.8	8
45	Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 8014-8014.	1.6	8
46	Primary bone marrow Hodgkin lymphoma in an HIV-negative patient. <i>International Journal of Hematology</i> , 2014, 99, 503-507.	1.6	7
47	Chimeric antigen receptor T cell therapy: Challenges and framework of outpatient administration. <i>EJHaem</i> , 2022, 3, 54-60.	1.0	6
48	Plasmablastic lymphoma of the retroperitoneum in an HIV- and HCV-positive patient: hard to diagnose and harder to treat. <i>Medical Oncology</i> , 2012, 29, 3529-3534.	2.5	5
49	Taking a BiTE out of the CAR T space race. <i>British Journal of Haematology</i> , 2021, 195, 689-697.	2.5	5
50	Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 1116-1123.	2.4	5
51	T-DM1-related carotenoderma and hand-foot syndrome. <i>Lancet, The</i> , 2015, 385, 1509-1510.	13.7	4
52	Relapsed subcutaneous panniculitis-like T cell lymphoma: role of haploidentical hematopoietic stem cell transplant. <i>Annals of Hematology</i> , 2017, 96, 2125-2126.	1.8	4
53	Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 347-350.	2.5	4
54	High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e513-e520.	0.4	4

#	ARTICLE	IF	CITATIONS
55	Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e273-e280.	0.4	4
56	Antimicrobial de-escalation in patients with high-risk febrile neutropenia: Attitudes and practices of adult hospital care providers. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2021, 1, .	0.5	4
57	Splenectomy or Rituximab in Steroid-Refractory Immune Thrombocytopenia (ITP): The Mayo Clinic Experience. <i>Blood</i> , 2016, 128, 3735-3735.	1.4	4
58	Baseline peripheral blood biomarkers associated with clinical outcome of advanced lung cancer in patients treated with anti-PD-1 antibody.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20599-e20599.	1.6	4
59	447â€¦Interim results of a phase 1 study of the novel engineered toxin body TAK-169 in patients with relapsed or refractory multiple myeloma. , 2021, 9, A475-A475.		4
60	Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience. <i>Blood</i> , 2020, 136, 33-34.	1.4	4
61	Pituitary Apoplexy During Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e691-e693.	0.4	3
62	Hemophagocytic Lymphohistiocytosis: Retrospective Analysis for Prognostic Factors. <i>Blood</i> , 2015, 126, 4615-4615.	1.4	3
63	Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).. <i>Journal of Clinical Oncology</i> , 2019, 37, e14019-e14019.	1.6	3
64	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3
65	Impact of autologous hematopoietic cell transplantation on disease burden quantified by nextâ€¦generation sequencing in multiple myeloma treated with quadruplet therapy. <i>American Journal of Hematology</i> , 2022, 97, 1170-1177.	4.1	3
66	Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 2727-2730.	1.3	2
67	Allogeneic haematopoietic cell transplantation after CAR Tâ€¦cell therapy: safe, effective and contentious. <i>British Journal of Haematology</i> , 2020, 189, 21-23.	2.5	2
68	Newâ€¦onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide. <i>EJHaem</i> , 2020, 1, 576-580.	1.0	2
69	Cost Analysis of R-CHOP <i>Versus</i> Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features. <i>Clinical Hematology International</i> , 2020, 2, 117.	1.7	2
70	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 295-298.	2.4	2
71	Reduction in the Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 277.e1-277.e6.	1.2	2
72	Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined <sc>CIBMTR</sc>/<sc>CMWP</sc> ofâ€¦<sc>EBMT</sc> analysis. <i>British Journal of Haematology</i> , 2022, 198, 785-789.	2.5	2

#	ARTICLE	IF	CITATIONS
73	CMV esophagitis: sequelae of radiation therapy. <i>Esophagus</i> , 2013, 10, 244-246.	1.9	1
74	Adoptive transfer of food allergy via unrelated allogeneic bone marrow transplant. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 96-97.	1.0	1
75	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. <i>Bone Marrow Transplantation</i> , 2021, 56, 20-29.	2.4	1
76	Chimeric antigen receptorâ€”T cell therapies: The changing landscape. <i>EJHaem</i> , 0, 3, 3.	1.0	1
77	Secondary Hemophagocytic Lymphohistiocytosis: A Rare Complication of Acute EBV Infection. <i>Chest</i> , 2016, 149, A146.	0.8	0
78	Outcomes of Primary Effusion Lymphoma: The Role of Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S291.	0.4	0
79	Hepatitis C Virus-associated Lymphoplasmacytic Lymphoma With WaldenstrÃ¶m Macroglobulinemia: Response to Direct-acting Antiviral Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e195-e199.	0.4	0
80	Efficacy of up-front hematopoietic cell transplantation in peripheral t-cell lymphoma, not otherwise specified (PTCL-NOS): A National Cancer Database analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7578-7578.	1.6	0
81	Clinical Outcomes and Cost Analysis of Dose-Adjusted R-EPOCH Vs R-CHOP in Treatment of Diffuse Large B- Cell Lymphoma with High Risk Features. <i>Blood</i> , 2018, 132, 4790-4790.	1.4	0
82	Oligoclonal gammaâ€”delta T cell expansion in response to <i>Ehrlichia</i> infection. <i>American Journal of Hematology</i> , 2022, 97, 1116-1117.	4.1	0
83	Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR. <i>Blood</i> , 2020, 136, 28-29.	1.4	0
84	Increased Incidence of New-Onset Diabetes Mellitus Type II Following Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease. <i>Blood</i> , 2020, 136, 20-20.	1.4	0
85	Reduced Insulin Sensitivity in Patients with Myeloid Malignancies and Clonal Hematopoiesis Mutations. <i>Blood</i> , 2020, 136, 27-28.	1.4	0
86	Reduction in Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 12-12.	1.4	0
87	Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT. <i>Blood</i> , 2020, 136, 5-6.	1.4	0